Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2020 Nov 19

PMID 33209025

Citations 1

Authors

Engin Emrem Bestepe

Nazli Tunali

Gokce Elif Saridogan

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Compliance and maintenance of abstinence is a major issue in substance use disorders. Adverse effects of opioid maintenance treatments (OMT) include sexual dysfunctions. There is a vast amount of studies regarding sexual adverse effects of conventional OMTs; however, information regarding buprenorphine/naloxone (Bup/Nal) combination is limited, mostly evaluated in western populations and controversial. In this study, we aimed to assess the sexual adversities of Bup/Nal treatment in a Turkish alcohol and substance use disorder treatment center sample.

Materials And Methods: We recruited 100 subjects continuing sublingual Bup/Nal combination and 35 control subjects. Subjects were evaluated via the the Golombok-Rust Inventory of Sexual Satisfaction (GRISS) for sexual dysfunction and for erectile dysfunction (ED) with the International Index of Erectile Function-5 (IIEF-5) as a comparison.

Results: The mean dose of our treatment was 9.05. Overall sexual dysfunction scores were not significantly different in between groups with GRISS. ED and noncommunication scores were significantly higher in the Bup/Nal treatment group than the control group (p = 0.002, p = 0.02, respectively). Along with the increased ED scores in GRISS, IIEF-5 total scores also revealed more significant severity of the ED in the Bup/Nal group (p = 0.001).

Conclusion: Buprenorphine/naloxone combination lead to a higher degree of ED severity than the non-treatment controls. Noncommunication seems to play a role as a risk factor for ED in patients with opioid use disorder. Thus, effective communication can be a key factor for sexual assertivity and disclosing the sexual adverse effects to the clinicians as well as staying in the treatment.

Citing Articles

Comparing attention, impulsivity, and executive functions between patients with opiate use disorder: Buprenorphine maintenance treatment versus active users, in comparison with healthy controls.

Keles D, Bilici R, Ayik B, Kilic M, Kliewer W Indian J Psychiatry. 2024; 66(1):90-97.

PMID: 38419927 PMC: 10898529. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_520_23.

References

Xia Y, Zhang D, Li X, Chen W, He Q, Jahn H . Sexual dysfunction during methadone maintenance treatment and its influence on patient's life and treatment: a qualitative study in South China. Psychol Health Med. 2012; 18(3):321-9. DOI: 10.1080/13548506.2012.729845. View

Johnson R, Strain E, Amass L . Buprenorphine: how to use it right. Drug Alcohol Depend. 2003; 70(2 Suppl):S59-77. DOI: 10.1016/s0376-8716(03)00060-7. View

Weber M, Smith D, OConnell D, Patel M, de Souza P, Sitas F . Risk factors for erectile dysfunction in a cohort of 108 477 Australian men. Med J Aust. 2013; 199(2):107-11. DOI: 10.5694/mja12.11548. View

Yee A, Loh H, Loh H, Riahi S, Ng C, Sulaiman A . A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment. Ann Gen Psychiatry. 2019; 18:25. PMC: 6805364. DOI: 10.1186/s12991-019-0249-z. View

Chen K, Chen L, Mao J . Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014; 120(5):1262-74. PMC: 3999180. DOI: 10.1097/ALN.0000000000000170. View

Quaglio G, Lugoboni F, Pattaro C, Melara B, Mezzelani P, Des Jarlais D . Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment. Drug Alcohol Depend. 2007; 94(1-3):12-8. DOI: 10.1016/j.drugalcdep.2007.09.025. View

Aguilar de Arcos F, Verdejo-Garcia A, Ceverino A, Montanez-Pareja M, Lopez-Juarez E, Sanchez-Barrera M . Dysregulation of emotional response in current and abstinent heroin users: negative heightening and positive blunting. Psychopharmacology (Berl). 2008; 198(2):159-66. DOI: 10.1007/s00213-008-1110-2. View

Baykara S, Alban K . The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients. Psychiatry Res. 2019; 272:450-453. DOI: 10.1016/j.psychres.2018.12.153. View

Rosen R, Cappelleri J, Smith M, Lipsky J, Pena B . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 2000; 11(6):319-26. DOI: 10.1038/sj.ijir.3900472. View

10.

Vallejo-Medina P, Sierra J . Effect of drug use and influence of abstinence on sexual functioning in a Spanish male drug-dependent sample: a multisite study. J Sex Med. 2012; 10(2):333-41. DOI: 10.1111/j.1743-6109.2012.02977.x. View

11.

Ramdurg S, Ambekar A, Lal R . Sexual dysfunction among male patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence. J Sex Med. 2011; 9(12):3198-204. DOI: 10.1111/j.1743-6109.2011.02219.x. View

12.

Cioe P, Friedmann P, Stein M . Erectile dysfunction in opioid users: lack of association with serum testosterone. J Addict Dis. 2010; 29(4):455-60. PMC: 2951625. DOI: 10.1080/10550887.2010.509279. View

13.

Zhao S, Deng T, Luo L, Wang J, Li E, Liu L . Association Between Opioid Use and Risk of Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2017; 14(10):1209-1219. DOI: 10.1016/j.jsxm.2017.08.010. View

14.

Osasona S, Ehimigbai M . Sexual dysfunction: prevalence and associated factors in patients with mental illness receiving psychotropic medication in Nigeria. Afr Health Sci. 2020; 19(4):2973-2984. PMC: 7040335. DOI: 10.4314/ahs.v19i4.18. View

15.

Lafisca S, Bolelli G, Franceschetti F, Filicori M, Flamigni C, Marigo M . Hormone levels in methadone-treated drug addicts. Drug Alcohol Depend. 1981; 8(3):229-34. DOI: 10.1016/0376-8716(81)90066-1. View

16.

Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmuller D . Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2004; 90(1):203-6. DOI: 10.1210/jc.2004-0929. View

17.

Teusch L, Scherbaum N, Bohme H, Bender S, Gastpar M . Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate.... Pharmacopsychiatry. 1995; 28(3):84-92. DOI: 10.1055/s-2007-979596. View

18.

Donatucci C, Lue T . Erectile dysfunction in men under 40: etiology and treatment choice. Int J Impot Res. 1993; 5(2):97-103. View

19.

Ajo R, Segura A, Inda M, Margarit C, Ballester P, Martinez E . Erectile dysfunction in patients with chronic pain treated with opioids. Med Clin (Barc). 2017; 149(2):49-54. DOI: 10.1016/j.medcli.2016.12.038. View

20.

Brown R, Balousek S, Mundt M, Fleming M . Methadone maintenance and male sexual dysfunction. J Addict Dis. 2005; 24(2):91-106. DOI: 10.1300/J069v24n02_08. View